XNYS · PHARMACEUTICAL PREPARATIONS · PHARMACEUTICAL PREPARATIONS
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
TL;DR: Zoetis grew Q1 2026 revenue 2.9% to $2.26B from $2.20B a year ago, while net income came in at $601 million, or $1.42 per diluted share.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 5/11/2026 | MCCALLISTER MICHAEL B | — | BUY | 3,000 | $78 | $233,273 |
| 4/30/2026 | Esch Kevin | Executive Vice President | OPTION_EXERCISE | 259 | — | — |
| 4/30/2026 | Esch Kevin | Executive Vice President | TAX_WITHHOLD | -75 | $115 | $8,623 |
| 4/30/2026 | Esch Kevin | Executive Vice President | OPTION_EXERCISE | -259.92 | — | — |
| 4/10/2026 | FULLER JULIE | Executive Vice President | GRANT | 550.64 | $40 | $21,828 |
| 4/10/2026 | Lagano Roxanne | Executive Vice President | GRANT | 550.64 | $40 | $21,828 |
| 4/10/2026 | Ferran Astorga Jeannette | Executive Vice President | GRANT | 5 | $40 | $198 |
| 4/10/2026 | Esch Kevin | Executive Vice President | GRANT | 1.39 | $40 | $55 |
| 4/10/2026 | PECK KRISTIN C | Chief Executive Officer | GRANT | 2,776.77 | $40 | $110,071 |
| 4/10/2026 | Driscoll Rimma | Executive Vice President | GRANT | 26.2 | $40 | $1,038 |
| 4/10/2026 | Joseph Wetteny | Chief Financial Officer | GRANT | 873.95 | $40 | $34,643 |
| 4/10/2026 | Sarbaugh Keith | Executive Vice President | GRANT | 230.76 | $40 | $9,147 |
| 3/31/2026 | Sarbaugh Keith | Executive Vice President | OPTION_EXERCISE | 1,528 | — | — |
| 3/31/2026 | Sarbaugh Keith | Executive Vice President | TAX_WITHHOLD | -524 | $118 | $61,942 |
| 3/31/2026 | Sarbaugh Keith | Executive Vice President | OPTION_EXERCISE | -1,528.02 | — | — |
| 3/27/2026 | FULLER JULIE | Executive Vice President | GRANT | 669.34 | $38 | $25,569 |
| 3/27/2026 | Joseph Wetteny | Chief Financial Officer | GRANT | 2,114.76 | $38 | $80,784 |
| 3/27/2026 | PECK KRISTIN C | Chief Executive Officer | GRANT | 4,391.26 | $38 | $167,746 |
| 3/27/2026 | Driscoll Rimma | Executive Vice President | GRANT | 641.74 | $38 | $24,515 |
| 3/27/2026 | Esch Kevin | Executive Vice President | GRANT | 219.95 | $38 | $8,402 |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| BlackRock | 36,835,040 | $6,385,722,454 | — | 8/13/2024 |
| Vanguard Group | 47,780,974 | $6,011,802,148 | — | 1/29/2026 |
| State Street | 19,796,891 | $2,490,844,826 | — | 2/13/2026 |
| JP Morgan Chase | 2,401,497 | $302,156,524 | — | 2/11/2026 |
| Citadel Advisors | 1,622,005 | $204,080,669 | — | 2/17/2026 |
| DE Shaw | 1,216,847 | $153,103,690 | — | 2/17/2026 |
| AQR Capital | 802,731 | $100,999,564 | — | 2/17/2026 |
| Fidelity (FMR) | 439,050 | $55,241,244 | — | 2/17/2026 |
| Millennium Management | 419,283 | $52,754,187 | — | 2/17/2026 |
| Bridgewater Associates | 182,559 | $22,969,573 | — | 2/13/2026 |
| Two Sigma | 110,718 | $13,930,539 | — | 2/17/2026 |
| Point72 | 5,700 | $717,174 | — | 2/17/2026 |